For Those Who Play The Stock Market
Palatin Sex drug near P3 Works on males and females. Also affects DESIRE.
Huge market. Palatin (ptn) and their partner King (KG)
1.) PT-141, recently named bremelanotide by international convention, is being developed as a treatment for erectile dysfunction (ED) and female sexual dysfunction (FSD) by Palatin Technologies, Inc. of New Jersey.
2.) Bremelanotide significantly promotes solicitational behavior in female rats, and appears to be the first true aphrodesiac. (See J. Pfaus et al., "Selective Facilitation of Sexual Solicitation in the Female Rat by a Melanocortin Agonist")
3.) In humans, bremelanotide produces an "enjoyable arousal response" and induces sexual desire within 10-20 minutes after intranasal administration, with the effects of bremelanotide continuing past orgasm.
4.) The effects of bremelanotide are in contrast to phosphodiesterase inhibitors such as Viagra, Levitra and Cialis, which do not induce subjective erotogenic effects in the absence of sexual stimulation.
This stock is very cheap at about 2.30 right now and has the potential to skyrocket once the FDA Approves.